Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What Will Be the Growth Trajectory of the Filgrastim Biosimilars Market from 2024 to 2033?

The market for filgrastim biosimilars has seen robust growth in the recent past. The market’s size is set to increase from $1.02 billion in 2023 to $1.1 billion in 2024, showing a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this significant growth during the historical period include the growth in emerging markets, an increase due to patent expirations, governmental initiatives, enhanced healthcare spending, affordable biosimilars, a promising drug pipeline, and augmented expenditure on biopharmaceutical research and development.

The filgrastim biosimilars market is forecasted to experience a swift expansion in the upcoming years, reaching a value of $1.66 billion by 2028, with a compound annual growth rate (CAGR) of 10.7%. The anticipated growth within this period can be credited to elements such as an aging population and increased access to healthcare. Key trends predicted for this period involve substantial investment in research and development activities in the pursuit of effective and innovative biosimilars, the manufacturing of biosimilars for the treatment of neutropenia to boost revenue, and an intensified focus on merger and acquisition strategies for growth.

Claim Your Free Sample of the Global Filgrastim Biosimilars Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Are the Primary Growth Drivers for the filgrastim biosimilars Market?

The filgrastim biosimilar market is anticipated to experience growth due to the rise in neutropenia cases. Neutropenia is a health condition involving a shortage of neutrophils, a key white blood cell type that helps with infection management. Filgrastim biosimilars enhance the number of neutrophils by promoting their production in the bone marrow, strengthening the body’s defense against infections. As revealed by a study from the National Center for Biotechnology Information in August 2022, neutropenia had shown a prevalence rate of 0.38% among Mexican Americans, 0.79% among whites, and 4.5% among black participants. Consequently, the growing rate of neutropenia significantly contributes to the expansion of the filgrastim biosimilar market.

What Are the Defining Segments of the Filgrastim Biosimilars Market?

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What Trends Are Revolutionizing Standards in the Filgrastim Biosimilars Market?

Leading firms in the filgrastim biosimilar sector are formulating novel products utilizing cutting-edge methods like recombinant DNA technology to generate biosimilars. This technology begins with the generation of hybrid or chimeric DNA by integrating a foreign sequence into an organism’s DNA. An example of this occurred in May 2023 when Amneal Pharmaceuticals introduced FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA in the US, for treating and preventing febrile neutropenia. It fosters the growth and specialization of neutrophils from specific progenitor cells, stimulates their maturation and enhances the effectiveness and lifespan of mature neutrophils, causing a dosage-related increase in neutrophil counts. The introduction of Fylnetra is pivotal for the upcoming era of cost-effective medications, promoting accessibility for patients, healthcare providers, and payors.

Order Now for Fast Delivery of Your Filgrastim Biosimilars Market Report!

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

What Regions Are Propelling Growth in the Filgrastim Biosimilars Industry?

North America was the largest region in the filgrastim biosimilar markets market in 2023. The Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Filgrastim Biosimilars Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the filgrastim biosimilars market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Filgrastim Biosimilars Market Include

1. Filgrastim Biosimilars Market Executive Summary

2. Filgrastim Biosimilars Market Segments

3. Filgrastim Biosimilars Market Size And Template Market Growth Rate

4. Key Filgrastim Biosimilars Market Trends

5. Major Filgrastim Biosimilars Market Drivers

……

25. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

26. Top Filgrastim Biosimilars Companies

27. Filgrastim Biosimilars Market Opportunities And Strategies

28. Filgrastim Biosimilars Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Trastuzumab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: